Compare FLOC & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FLOC | EVO |
|---|---|---|
| Founded | 1996 | 1993 |
| Country | United States | Germany |
| Employees | 1281 | 4553 |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 944.8M | 934.1M |
| IPO Year | N/A | N/A |
| Metric | FLOC | EVO |
|---|---|---|
| Price | $27.35 | $3.01 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 1 |
| Target Price | ★ $28.50 | $7.00 |
| AVG Volume (30 Days) | ★ 588.4K | 85.0K |
| Earning Date | 05-06-2026 | 04-08-2026 |
| Dividend Yield | ★ 1.31% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $22.92 | $1.37 |
| Revenue Next Year | $8.59 | $10.05 |
| P/E Ratio | $16.57 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $14.03 | $2.31 |
| 52 Week High | $28.26 | $4.48 |
| Indicator | FLOC | EVO |
|---|---|---|
| Relative Strength Index (RSI) | 64.93 | 53.04 |
| Support Level | $14.96 | $2.88 |
| Resistance Level | N/A | $3.36 |
| Average True Range (ATR) | 1.08 | 0.09 |
| MACD | 0.09 | -0.01 |
| Stochastic Oscillator | 81.76 | 54.34 |
Flowco Holdings Inc is a provider of production optimization, artificial lift, emissions management, and monetization solutions for the oil and natural gas industry. Its technologies include high-pressure gas lift (HPGL), conventional gas lift, plunger lift, and vapor recovery unit (VRU) solutions. The company operates in two reportable segments: Production Solutions, which includes rental services, and Natural Gas Technologies, which include service, gas compression parts, and equipment sales. Production Solutions: relates to rentals, sales, and services related to high-pressure gas lift, conventional gas lift, and plunger lift; including other digital solutions and methane abatement technologies, and has maximum revenue. It generates maximum revenue from the United States.
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.